<p>Indivior（纳斯达克代码：INDV）在发布一项新的多中心临床试验结果后引起了关注，该试验考察了 SUBLOCADE 的启动方法，这是一种延释布洛芬治疗。数据显示，尤其是对于使用芬太尼的患者，保留率更高，患者参与度更好。</p>
<p>查看我们对 Indivior 的最新分析。</p>
<p>Indivior 最新的临床里程碑是在强劲的股票势头下取得的，年初至今股价回报率为 99.2%，一年总股东回报率达到惊人的 190.9%。虽然 SUBLOCADE 改善结果的消息增加了积极前景，但近期的举动也反映出对 Indivior 长期战略和不断演变的风险状况的信心日益增强。随着创新和市场情绪的结合，势头显然在增强。</p>
<p>如果像 SUBLOCADE 这样的创新让你思考该行业的未来，现在是探索的好时机。查看完整列表，免费获取。</p>
<p>今年股价上涨近 100%，临床势头加速，投资者正在考虑 Indivior 当前的估值是否为长期投资的良机，或者市场是否已经反映了 SUBLOCADE 增长故事的潜力。</p>
<h2>市盈率 58.6 倍：是否合理？</h2>
<p>在最后收盘价为 24.90 美元的情况下，Indivior 的市盈率（P/E）高达 58.6 倍，显著高于其行业同行。考虑到该公司的估值与美国制药行业其他公司的快速上升，这一数字尤为突出。</p>
<p>市盈率衡量投资者愿意为公司每一美元的收益支付多少。对于像 Indivior 这样的制药公司，高市盈率可能反映出对未来增长的强烈预期或对突破性产品的乐观态度。</p>
<p>在 Indivior 的案例中，当前的市盈率显著超过同行平均水平（21.4 倍）和更广泛的美国制药行业平均水平（18.4 倍）。市场似乎在定价远高于竞争对手的收益增长。然而，与估计的合理市盈率 29.6 倍相比，当前的倍数看起来昂贵，如果预计的增长放缓，可能会引起未来的审查。</p>
<p>探索 Indivior 的 SWS 合理比率</p>
<p><strong>结果：市盈率 58.6 倍（被高估）</strong></p>
<p>然而，收入增长放缓或临床采用的任何挫折可能会迅速挑战目前支持 Indivior 高估值的乐观情绪。</p>
<p>了解 Indivior 叙述中的关键风险。</p>
<h2>另一种观点：折现现金流显示深度价值</h2>
<p>超越传统的市盈率比较，我们的 SWS DCF 模型为 Indivior 提供了显著不同的视角。该模型估计每股公允价值为 69.61 美元，这表明该股票的交易价格有 64.2% 的折扣。市场是否忽视了某些关键因素，还是这只是太美好而不真实？</p>
<p>了解 SWS DCF 模型如何得出其公允价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7f3d774b-d891-4456-9b1a-a4b9d0601479/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7f3d774b-d891-4456-9b1a-a4b9d0601479/chart/dcf"/></p>
<p>截至 2025 年 10 月的 INDV 折现现金流</p>
<p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Indivior）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器根据现金流发现被低估的股票。如果您保存筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
<h2>构建您自己的 Indivior 叙述</h2>
<p>如果这种观点与您的看法不完全一致，或者您更愿意根据数字得出自己的结论，您可以在几分钟内通过 “按您的方式” 塑造您独特的 Indivior 叙述。</p>
<p>您进行 Indivior 研究的一个很好的起点是我们的分析，强调了可能影响您投资决策的 3 个关键奖励和 3 个重要警示信号。</p>
<h2>寻找更多投资想法？</h2>
<p>不要让您下一个伟大的股票从雷达上消失。通过今天查看这些有针对性的机会，为更聪明的投资决策做好准备：</p>
<ul>
<li>通过发现 871 只基于现金流的被低估股票，利用强劲的现金流潜力，抓住被低估的公司，趁市场尚未察觉。</li>
<li>通过跟踪这 17 只收益率超过 3% 的股息股票，为您的投资组合提供长期动力，提供超过 3% 的突出收益。</li>
<li>领先于变革性创新，关注这些 26 只在人工智能进步中引领潮流的 AI 便士股票，抓住突破性机会。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

INDV

<p>Indivior（纳斯达克代码：INDV）因 SUBLOCADE 的临床试验结果积极而受到关注，显示出患者留存率有所改善，尤其是在芬太尼用户中。该股今年迄今已上涨 99.2%，市盈率为 58.6 倍，显著高于行业同行。虽然这表明强劲的增长预期，但也可能表明相对于估计的合理市盈率 29.6 倍的高估。折现现金流分析将该股的价值评估为 69.61 美元，显示出 64.2% 的折扣。投资者正在权衡长期增长的潜力与当前市场乐观情绪之间的关系</p>

<p>Indivior (NasdaqGS:INDV) has drawn attention after releasing results from a new multicenter clinical trial examining initiation methods for SUBLOCADE, its extended-release buprenorphine therapy. The data signals higher retention rates and better patient engagement, especially for those with fentanyl use.</p>
<div class="lb-trans"><p>Indivior（纳斯达克代码：INDV）在发布一项新的多中心临床试验结果后引起了关注，该试验考察了 SUBLOCADE 的启动方法，这是一种延释布洛芬治疗。数据显示，尤其是对于使用芬太尼的患者，保留率更高，患者参与度更好。</p>
</div><p>See our latest analysis for Indivior.</p>
<div class="lb-trans"><p>查看我们对 Indivior 的最新分析。</p>
</div><p>Indivior's latest clinical milestone comes on the back of powerful stock momentum, with a 99.2% year-to-date share price return and a remarkable 190.9% total shareholder return over one year. While the news of SUBLOCADE's improved outcomes adds to the positive outlook, recent moves also reflect growing confidence in Indivior's long-term strategy and evolving risk profile. Momentum is clearly building as both innovation and market sentiment align.</p>
<div class="lb-trans"><p>Indivior 最新的临床里程碑是在强劲的股票势头下取得的，年初至今股价回报率为 99.2%，一年总股东回报率达到惊人的 190.9%。虽然 SUBLOCADE 改善结果的消息增加了积极前景，但近期的举动也反映出对 Indivior 长期战略和不断演变的风险状况的信心日益增强。随着创新和市场情绪的结合，势头显然在增强。</p>
</div><p>If innovations like SUBLOCADE have you thinking about what's next in the sector, now’s a great time to explore See the full list for free.</p>
<div class="lb-trans"><p>如果像 SUBLOCADE 这样的创新让你思考该行业的未来，现在是探索的好时机。查看完整列表，免费获取。</p>
</div><p>With shares gaining nearly 100% this year and clinical momentum accelerating, investors are considering whether Indivior’s current valuation presents a bargain for the long term or if the market already reflects the potential of SUBLOCADE’s growth story.</p>
<div class="lb-trans"><p>今年股价上涨近 100%，临床势头加速，投资者正在考虑 Indivior 当前的估值是否为长期投资的良机，或者市场是否已经反映了 SUBLOCADE 增长故事的潜力。</p>
</div><h2>Price-to-Earnings of 58.6x: Is it justified?</h2>
<div class="lb-trans"><h2>市盈率 58.6 倍：是否合理？</h2>
</div><p>At a last close price of $24.90, Indivior trades at a hefty price-to-earnings (P/E) ratio of 58.6x, which is notably higher than its industry peers. This figure stands out given how rapidly the company’s valuation has risen compared to others in the US Pharmaceuticals sector.</p>
<div class="lb-trans"><p>在最后收盘价为 24.90 美元的情况下，Indivior 的市盈率（P/E）高达 58.6 倍，显著高于其行业同行。考虑到该公司的估值与美国制药行业其他公司的快速上升，这一数字尤为突出。</p>
</div><p>The price-to-earnings ratio measures how much investors are willing to pay for each dollar of a company’s earnings. For pharmaceutical companies like Indivior, a high P/E ratio can reflect strong expectations for future growth or optimism about breakthrough products.</p>
<div class="lb-trans"><p>市盈率衡量投资者愿意为公司每一美元的收益支付多少。对于像 Indivior 这样的制药公司，高市盈率可能反映出对未来增长的强烈预期或对突破性产品的乐观态度。</p>
</div><p>In Indivior’s case, the current P/E multiple significantly exceeds both the peer average (21.4x) and the broader US Pharmaceuticals industry average (18.4x). The market appears to be pricing in earnings growth far greater than competitors. However, compared to the estimated fair P/E ratio of 29.6x, the current multiple looks expensive and may attract future scrutiny if delivery on projected growth slows.</p>
<div class="lb-trans"><p>在 Indivior 的案例中，当前的市盈率显著超过同行平均水平（21.4 倍）和更广泛的美国制药行业平均水平（18.4 倍）。市场似乎在定价远高于竞争对手的收益增长。然而，与估计的合理市盈率 29.6 倍相比，当前的倍数看起来昂贵，如果预计的增长放缓，可能会引起未来的审查。</p>
</div><p>Explore the SWS fair ratio for Indivior</p>
<div class="lb-trans"><p>探索 Indivior 的 SWS 合理比率</p>
</div><p><strong>Result: Price-to-Earnings of 58.6x (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：市盈率 58.6 倍（被高估）</strong></p>
</div><p>However, slower revenue growth or any setbacks in clinical adoption could quickly challenge the optimism that currently supports Indivior’s elevated valuation.</p>
<div class="lb-trans"><p>然而，收入增长放缓或临床采用的任何挫折可能会迅速挑战目前支持 Indivior 高估值的乐观情绪。</p>
</div><p>Find out about the key risks to this Indivior narrative.</p>
<div class="lb-trans"><p>了解 Indivior 叙述中的关键风险。</p>
</div><h2>Another View: Discounted Cash Flow Shows Deep Value</h2>
<div class="lb-trans"><h2>另一种观点：折现现金流显示深度价值</h2>
</div><p>Looking beyond traditional price-to-earnings comparisons, our SWS DCF model presents a significantly different perspective for Indivior. The model estimates the fair value at $69.61 per share, which indicates that the stock is trading at a steep 64.2% discount. Is the market overlooking something crucial, or is this simply too good to be true?</p>
<div class="lb-trans"><p>超越传统的市盈率比较，我们的 SWS DCF 模型为 Indivior 提供了显著不同的视角。该模型估计每股公允价值为 69.61 美元，这表明该股票的交易价格有 64.2% 的折扣。市场是否忽视了某些关键因素，还是这只是太美好而不真实？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>了解 SWS DCF 模型如何得出其公允价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7f3d774b-d891-4456-9b1a-a4b9d0601479/chart/dcf" alt="" original-src="https://images.simplywall.st/company/7f3d774b-d891-4456-9b1a-a4b9d0601479/chart/dcf"/></p>
<p>INDV Discounted Cash Flow as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 INDV 折现现金流</p>
</div><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Indivior for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p>
<div class="lb-trans"><p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Indivior）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器根据现金流发现被低估的股票。如果您保存筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
</div><h2>Build Your Own Indivior Narrative</h2>
<div class="lb-trans"><h2>构建您自己的 Indivior 叙述</h2>
</div><p>If this perspective doesn't quite match your own, or you’d rather draw your own conclusions from the numbers, you can shape your unique Indivior narrative in just a few minutes with Do it your way</p>
<div class="lb-trans"><p>如果这种观点与您的看法不完全一致，或者您更愿意根据数字得出自己的结论，您可以在几分钟内通过 “按您的方式” 塑造您独特的 Indivior 叙述。</p>
</div><p>A great starting point for your Indivior research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.</p>
<div class="lb-trans"><p>您进行 Indivior 研究的一个很好的起点是我们的分析，强调了可能影响您投资决策的 3 个关键奖励和 3 个重要警示信号。</p>
</div><h2>Looking for More Investment Ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>Don't let your next great stock slip off the radar. Set yourself up for smarter moves by checking out these targeted opportunities today:</p>
<div class="lb-trans"><p>不要让您下一个伟大的股票从雷达上消失。通过今天查看这些有针对性的机会，为更聪明的投资决策做好准备：</p>
</div><ul>
<li>Capitalize on strong cash flow potential by spotting compelling bargains through these 871 undervalued stocks based on cash flows and seize undervalued companies before the market catches on.</li>
<li>Power your portfolio for the long term by tracking reliable payouts with these 17 dividend stocks with yields &gt; 3%, offering standout yields above 3%.</li>
<li>Get ahead of transformative innovation and zero in on breakthrough opportunities with these 26 AI penny stocks leading the way in artificial intelligence advancements.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过发现 871 只基于现金流的被低估股票，利用强劲的现金流潜力，抓住被低估的公司，趁市场尚未察觉。</li>
<li>通过跟踪这 17 只收益率超过 3% 的股息股票，为您的投资组合提供长期动力，提供超过 3% 的突出收益。</li>
<li>领先于变革性创新，关注这些 26 只在人工智能进步中引领潮流的 AI 便士股票，抓住突破性机会。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

审视 Indivior (INDV) 在 SUBLOCADE 新临床试验结果公布后的估值